SCHEDULE 13G/A: Todd Hale Morrison Discloses 9.1% Stake in BioRestorative Therapies

Todd Hale Morrison has filed an amended Schedule 13G, disclosing beneficial ownership of approximately 9.1% of BioRestorative Therapies, Inc.'s common stock as of February 18, 2025.

Summary

• Todd Hale Morrison, an individual, has filed an Amendment No. 1 to Schedule 13G regarding BioRestorative Therapies, Inc. (BRTX).
• As of the close of business on February 18, 2025, Mr. Morrison beneficially owned 630,000 shares of BioRestorative Therapies, Inc. common stock.
• This ownership represents approximately 9.1% of the Issuer's outstanding common stock.
• The percentage was calculated based on 6,919,919 shares of common stock outstanding as of November 12, 2024, as reported in the Issuer's Form 10-Q.
• Mr. Morrison holds shared voting power and shared dispositive power over all 630,000 shares.
• The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Sentiment

Score: 6

Explanation: The filing is a factual disclosure of a significant beneficial ownership stake. While it doesn't contain explicit positive or negative financial news, a substantial individual stake can be interpreted as a sign of investor confidence. The mention of potential nomination activities under Rule 240.14a-11 introduces a slight element of potential future shareholder engagement.

Positives

• The disclosure of a significant stake (9.1%) by an individual investor like Todd Hale Morrison can signal confidence in BioRestorative Therapies, Inc.'s long-term prospects.
• The filing explicitly states that the shares were not acquired for the purpose of changing or influencing control, which may alleviate concerns about hostile takeovers or disruptive activism, with the exception of potential nomination activities.

Risks

• The filing notes that the securities were not acquired for the purpose of changing or influencing control, 'other than activities solely in connection with a nomination under 240.14a-11.' This clause indicates a potential for shareholder activism related to board nominations, which could lead to future management changes or strategic shifts within BioRestorative Therapies, Inc.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding BioRestorative Therapies, Inc.'s future operations or financial performance, focusing solely on the beneficial ownership disclosure.

Industry Context

This filing is a standard regulatory disclosure of a significant ownership stake by an individual investor in a publicly traded company. While the specific industry of BioRestorative Therapies, Inc. (likely biotechnology or regenerative medicine given its name) is not detailed in this filing, such disclosures are common across all sectors and provide transparency regarding major shareholders.

Comparison to Industry Standards

• This Schedule 13G filing is a standard regulatory disclosure and does not provide financial or operational results that can be compared to industry benchmarks or specific comparable companies. It solely details a beneficial ownership stake in BioRestorative Therapies, Inc.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an individual investor provides transparency regarding the ownership structure and may influence investor sentiment. The potential for nomination activities under Rule 240.14a-11 could lead to future changes in board composition or strategic direction, impacting all shareholders.

Key Dates

Keywords

BioRestorative Therapies, BRTX, Todd Hale Morrison, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Shareholder Stake, Investment, Biotechnology